For a second year in a row, Currax delivered greater than 50% year-over-year revenue growth for CONTRAVE®/MYSIMBA® in 2024. These outsized results were driven by increased patient demand, improved ...
A total of £370,000 is set to be awarded as grants for research projects in the charity’s largest-ever funding round ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback